Emerging at the UK, retatrutide, a novel compound , is creating considerable buzz within the medical community regarding its promise for weight regulation. This dual GIP and GLP-1 target agonist looks to provide a substantial advantage over current therapies, showing positive results in initial clinical studies . Researchers suggest its distinctive